Supplementary Methods

SI Datasets
The base data used in this project is collected from the work of Sanchez-Valle et al. [7] . It consists of multiple datasets of gene expressions captured by micro-array technology [9] . The datasets are downloaded from Gene Expression Omnibus (GEO, [1] ) and ArrayExpress [2] databases. Each dataset contains measurements from healthy (controls) and affected (patients) subjects. For a given dataset, the measurements originate from bulk samples extracted from the same tissue in each subject. Not all datasets use the same tissue for measurements, as diseases do not necessarily affect the same tissue. Each patient is diagnosed with a single disease. For comparisons, the data is normalized by using the frozen robust multiarray procedure [4] to remove experimental bias. Furthermore, to remove tissue effects, each patient sample is normalised against all the control samples of its original dataset using the Limma method [10] . Up to this point, the data is identical to those used to derive the DMSN network [7] . Then we use the corrected p-values output by Limma to define for each patient a vector of size corresponding to the number of genes and in which the i th entry is equal to 1, −1, or 0 depending on whether the i th gene is significantly (with 5% cutoff) over-, under-, or normally expressed, respectively, for that patient. Additionally, we exclude patients that have no significantly deregulated genes, as we cannot learn anything from them.
The set of diseases is curated by hand for associations with Disease Ontology codes [8] , standard ICD9 and ICD10 codes, MeSH terms and OMIM codes [5] . Some of the datasets come from studies investigating subtypes of diseases that are studied by projects linked to other datasets. Based on the number of patients in each study, those datasets were either merged with the more global disease, or the patients associated with the more global disease were dropped from the study. Specifically, we drop the global disease if the subtype has many more patients associated with it and merge otherwise. Finally, we exclude diseases that have less than 10 associated patients to capture disease heterogeneity in the final dataset and to have sufficient data for each disease to split in a training and testing set.
SI Model
A neural network can be expressed as a series of matrix multiplications interleaved with non-linear functions, formally the output Y of a neural network with n − 1 hidden layers can be written as Y = f n (W n f n−1 (. . . f 1 ((W 1 X))) where X represents the input data, W i the weights of layer i, and f i (·) the non-linear function applied to the output of the i th layer. The optimization problem can be written as the minimization of the loss function L = g Ŷ , Y , whereŶ is the objective, or ground truth, and g(·) is a predefined function. Multinomial logistic regression (MLR) and the proposed GDP architecture can be written as
where s is the softmax function, typically used for multiclass classification problems and tanh denotes the hyperbolic tangent. Matrices X andŶ represent our data. Each column of X corresponds to the differential gene expression of a patient, and each column ofŶ corresponds to a patient's diagnosis (the prediction of which is the objective of the framework). W 1 ∈ R n d ×ng and W 2 2 ∈ R n d ×np correspond to fully-connected layers. The layer corresponding to W 2 1 ∈ R nc×ng represents biological pathway membership of the genes, i.e. the trainable weights of the matrix correspond only to entries (i, j) where gene j is part of the i th protein complex.
SI Methods Formally, the local variations δf of a single-argument function f due to a change δx = x − x 0 in input can be approximated with the first order Taylor expansion as
Thus, the magnitude of the local variations of f with respect to perturbation δx from x 0 is given by | df dx (x 0 )|. Based on this approximation, we extract from each neural network a score between an entity represented by a unit of the neural network (e.g, a pathway, or a gene) and each disease (output unit). Specifically, for a neural network NN, we denote nn i : [0, 1] n i → R no the function corresponding to the operation of a neural network NN from the n i outputs of layer i to the final n o logits of the neural network, i.e. scores before softmax. E.g., for GPD, we have nn 1 2 (x) = W 2 2 tanh (W 2 1 x). Then, the association score s i,j,k between the j th output unit of layer i, denoted u i j , of neural network NN, and disease k is given by
where the reference point is chosen as the null vector, x 0 = 0, which corresponds implicitly to a healthy state in our formulation.
SI Metrics
The cross-entropy loss (CLE) of a classifier is defined as
where m represents the number of samples (patients), n the number of classes (diseases), y ij indicates if patient i is diagnosed with disease j (1 if true 0 otherwise), andŷ ij is the j th output value of the classifier for patient i. A relatively small CEL means that the output probability distribution of a classifier is closer to the deterministic one-hot encoding of the true labeling, i.e. the classifier gives a higher probability to the true class and a very small probability to the other classes. The micro-averaged precision (Pre µ ) of a classifier gives a measure of the overall precision of the classifier and is defined as
where tp corresponds to the number of accurately classified patients and m represents the number of patients. The macro-averaged precision (Pre M ) of a classifer gives an average of the precision across the different classes (diseases) and is defined as
where tp i corresponds to the number of accurately classified patients for disease i and m i represents the number of patients diagnosed with the same disease. Pre M can be more informative than Pre µ when considering the problem with class imbalance.
SI Baselines
The Frequency of Differential Expression (FDE) score of a disease-gene association corresponds to how frequently that gene is consistently differentially expressed in patients having the disease, i.e., for disease d and gene g, the association score, s dg , is given by
where we amalgamate entities (disease, gene, and patient) with their indices, P d denotes the set of patients having disease d, and X corresponds to the data matrix introduced in Methods. The Katz method uses disease specific Protein-Protein Interaction (PPI) network, where each node of a standard PPI network is associated to a score (here the FDE of each gene for the disease considered). The authors then use Katz-centrality on each disease PPI network to extract a final score for each disease-gene association (here we use the absolute value). The higher the score, the higher the association is expected to be true. We download the PPI data from BioGRID [6] and IID [3] and create our PPI network from the union of both databases restricted to our set of genes. Finally, we perform a grid-search to identify the best parameters for the model by trying to maximise the area under the precision-recall curve metric. 
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